Organon Sustainability Profile
Organon & Co., a global healthcare company headquartered in the United States, focuses on women's health, biosimilars, and other critical therapeutic areas. Founded in 2021, Organon emerged as a spin-off from Merck & Co., marking a significant milestone in the pharmaceutical industry. The company is dedicated to addressing unmet medical needs through innovative products and services, particularly in reproductive health and chronic conditions. With a robust portfolio that includes contraceptives, hormone therapies, and biosimilars, Organon distinguishes itself by prioritising women's health and empowering patients. The company has quickly established a strong market position, recognised for its commitment to improving health outcomes and enhancing access to essential medications. As it continues to expand its global footprint, Organon remains focused on delivering impactful solutions that resonate with healthcare providers and patients alike.
DitchCarbon Score
How does Organon's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Organon's score of 34 is higher than 54% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Organon's reported carbon emissions
In 2023, Organon reported total carbon emissions of approximately 11,044,000 kg CO2e, comprising 2,272,000 kg CO2e from Scope 1, 5,557,000 kg CO2e from Scope 2, and 3,215,000 kg CO2e from Scope 3 emissions. This reflects a significant reduction from 2022, when total emissions were approximately 15,699,000 kg CO2e, with Scope 1 emissions at 1,122,000 kg CO2e, Scope 2 at 5,677,000 kg CO2e, and Scope 3 at 8,900,000 kg CO2e. Organon has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 greenhouse gas emissions by more than 25% from 2020 levels by 2025. This target is part of their broader sustainability strategy, which focuses on minimising their environmental impact while maintaining operational efficiency. The emissions data is not cascaded from any parent organisation, and all figures are reported directly by Organon. The company continues to monitor and report its emissions transparently, aligning with industry standards for climate accountability.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 30,521,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 32,908,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | 0,000,000,000 |
How Carbon Intensive is Organon's Industry?
How Carbon Intensive is Organon's Location?
Organon's Scope 3 Categories Breakdown
The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 74% of Scope 3 emissions.
Top Scope 3 Categories
Organon's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Organon has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
